GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Change In Payables And Accrued Expense

Nyrada (ASX:NYR) Change In Payables And Accrued Expense : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Change In Payables And Accrued Expense?

Nyrada's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Nyrada's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Nyrada's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Nyrada's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

Nyrada Change In Payables And Accrued Expense Historical Data

The historical data trend for Nyrada's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Change In Payables And Accrued Expense Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Change In Payables And Accrued Expense
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Payables And Accrued Expense Get a 7-Day Free Trial - - - - -

Nyrada Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nyrada's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
ASX:ANR ASX:HXL ASX:EX1 ASX:RGS ASX:NC6 ASX:ILA ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Website
https://www.nyrada.com
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines